Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242977 | 0.91 | ADORA2A (0.47) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL241156 | 0.90 | ADORA2A (0.40) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL2090952 | 0.90 | ADORA2A (0.45) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL242180 | 0.90 | ADORA2A (0.42) | ADORA2AADORA3 | |
| SCHEMBL243678 | 0.89 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL1402121 | 0.89 | ADORA2A (0.39) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL242722 | 0.89 | ADORA2A (0.42) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL240204 | 0.89 | ADORA2A (0.40) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL243058 | 0.89 | ADORA2A (0.39) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL1402053 | 0.89 | ADORA2A (0.40) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.